NCT03371797View on ClinicalTrials.gov

Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial

CompletedOBSERVATIONAL

Enrollment

800

Participants

Timeline

Start Date

February 20, 2018

Primary Completion Date

October 1, 2018

Study Completion Date

November 5, 2018

Conditions

Essential Hypertension

Interventions

DRUG

Valsartan, Amlodipine -

"Valsartan is a non-peptide, orally active, and specific angiotensin II receptor blocker acting on the AT1 receptor subtype used as an antihypertensive agent.~Amlodipine besylate is a dihydropyridine long-acting calcium channel blocker."

Trial Locations (1)

75290

Medicell, Karachi

All Listed Sponsors

lead

PharmEvo Pvt Ltd

INDUSTRY

NCT03371797 - Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial | Biotech Hunter | Biotech Hunter